Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization - TIGER-BVS

Fundació Clínic per a la Recerca Biomèdica0 个研究点目标入组 100 人开始时间: 2014年5月22日最近更新: 2019年12月10日

试验速览

暂无简介。

•a.Patients of both sexes, more than 18 years old.
•b. Written informed consent obtained.
•c. Patients with stable angina pectoris (Canadian Cardiovascular Society (CCS) Class 1, 2, 3 or 4) or patients with documented silent ischemia by stress test during the last year.
•d. Patients eligible for coronary revascularization in a coronary chronic total occlusion, which was angiographically documented in a previous coronary angiography during the last year.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 100

•a. Women who are pregnant or women of childbearing potential who do not use adequate contraception.
•b. Known allergies to aspirin, clopidogrel bisulfate (Plavix ®), ticagrelor (BriliqueTM) heparin, or a sensitivity to contrast media, which cannot be adequately pre-medicated.
•c. Participation in other studies.
•d. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult.
•e. Planned cardiac surgery or major non-cardiac surgery.
•f. The subject has a history of bleeding diathesis or coagulopathy.
•g. The subject suffered disabling stroke within the past year.
•h. Known major hematologic, neoplastic, metabolic, gastrointestinal or endocrine dysfunction, which, in the judgment of the Investigator, may affect the patient?s ability to complete the study.
•i. History of malignancy, except in patients who have been disease-free >5 years or whose only malignancy has been basal or squamous cell skin carcinoma.
•j. Inability to provide informed consent.

发起方

Fundació Clínic per a la Recerca Biomèdica